Mode
Text Size
Log in / Sign up
N/A N=50 Randomized Single-blind Treatment

Live Video Mind-body Treatment to Prevent Persistent Symptoms Following mTBI

MTBI - Mild Traumatic Brain Injury · Anxiety

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Number of Participants Who Scored Above the Midpoint on Each Subscale of the Credibility and Expectancy Questionnaire (CEQ) — 21; 23; 16; 19 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
TOR-C 1 (Behavioral); TOR-C 2 (Behavioral)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Jul 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Who Scored Above the Midpoint on Each Subscale of the Credibility and Expectancy Questionnaire (CEQ)
21; 23; 16; 19
PRIMARY
Number of Participants Who Scored Above the Midpoint on the Client Satisfaction Scale
20; 20
PRIMARY
Feasibility of Recruitment
50
PRIMARY
Acceptability of Treatment
21; 23
PRIMARY
Adherence to Homework
16
PRIMARY
Therapist Adherence
96.30; 97.60
PRIMARY
Feasibility of Assessments at Baseline
25; 25
PRIMARY
Feasibility of Assessments at Post-Test
22; 24
PRIMARY
Feasibility of Assessments at Follow-up
20; 23
PRIMARY
Adverse Events
0; 0
SECONDARY
Numerical Rating Scale
4.12; 5.20; 3.20; 3.72; 1.91; 3.50
SECONDARY
Post-Concussion Symptom Scale (PCSS)
43.52; 50.61; 12.50; 29.08; 11.65; 23.13
SECONDARY
Generalized Anxiety Disorder Scale (GAD-7)
10.00; 13.48; 5.00; 7.92; 3.85; 6.74
SECONDARY
Hospital Anxiety And Depression Scale (HADS)
9.46; 11.80; 6.02; 8.22; 7.81; 8.79
SECONDARY
World Health Organization - Disability Assessment Schedule 2.0 (WHODAS)
13.47; 16.29; 5.61; 9.83; 3.10; 7.61
SECONDARY
Fear Avoidance Behavior After Traumatic Brain Injury (FAB-TBI)
39.01; 44.45; 24.51; 36.02; 24.20; 31.35
SECONDARY
Pain Catastophizing Scale (PCS)
17.13; 20.64; 8.44; 14.46; 7.80; 13.22
SECONDARY
Cognitive And Affective Mindfulness Scale-Revised (CAMS-R)
29.31; 27.24; 33.68; 30.21; 33.65; 31.13
SECONDARY
Behavioral Response To Illness (BRIQ) - Limiting Behaviors Subscale
14.88; 17.28; 6.14; 11.00; 4.99; 9.83
SECONDARY
Behavioral Response To Illness (BRIQ) - All-or-Nothing Subscale
11.64; 12.84; 8.19; 10.79; 7.16; 9.52

Summary

The investigator aims to conduct a pilot randomized controlled trial to test the feasibility of two symptom management programs for college-age individuals with recent concussions and anxiety, TOR-C 1 and TOR-C 2. The investigator will assess the feasibility of recruitment procedures (screening, eligibility, and enrollment) and data collection as well as the feasibility, credibility, and acceptability of the programs (adherence, retention, fidelity, and satisfaction), following prespecified benchmarks. Both programs will be delivered virtually (Zoom).

Eligibility Criteria

Inclusion Criteria

  • Male and female outpatients, ages 18-35
  • English fluency and literacy
  • Diagnosed with a concussion in the past 10 weeks
  • Owns a smartphone or computer with Internet access
  • Willingness and ability to participate in four 45-minute program sessions and answer remote questionnaires before, after, and 3-month following the program
  • Free of concurrent psychotropic or have been on stable dosage for at least 6 weeks
  • Clinically significant anxiety symptoms (score ≥ 5 on GAD-7 anxiety scale)

Exclusion Criteria

  • Previous history of moderate or severe TBI OR concussion in the past 2 years that resulted in symptoms lasting 3 months or more
  • Diagnosed with a medical illness expected to worsen in the next 6 months (e.g., malignancy)
  • Lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder
  • Current substance abuse or dependence and current substance use disorder
  • Current active self-reported suicidal ideation
  • Practice of mindfulness techniques for greater than 45 minutes per week within the last 3 months
  • Participation in a mind-body or CBT treatment in the past 3 months
  • Currently pregnant
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05524402). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search